BioNTech Halts Colorectal Cancer Vaccine Trial Over Survival Imbalance
An independent safety board flagged the imbalance in trial BNT122-01, testing autogene cevumeran alone in resected Stage II-III colorectal cancer.
- Trial BNT122-01 tested autogene cevumeran alone in resected Stage II-III colorectal cancer patients.
- BioNTech's Aug. 28 statement cites 'a numerical imbalance in overall survival,' not which arm fared worse.
- Genentech, part of Roche, co-developed the shot; a pancreatic-cancer combination trial continues unaffected.
Why it matters: BioNTech named the imbalance and stopped; the claim about which arm died faster came from outside the company.